Navigation Links
Scottish medical charity and international drug consortium form partnership
Date:1/26/2012

Developing World Health (DWH), a leading medical charity based in Stirlingshire, Scotland and committed to developing effective treatments for neglected tropical diseases, has signed a collaboration agreement with the internationally respected Consortium for Parasitic Drug Development (CPDD), based at The University of North Carolina at Chapel Hill.

The collaboration agreement to develop new drugs is believed to be the first between a UK medical charity and international scientific consortium focused on neglected tropical diseases.

An estimated 16% of the world's population suffer from one or more neglected tropical diseases with 90% of cases recorded in Africa.

The agreement may prove highly lucrative, potentially generating in excess of $15 million investment in drug development for NTDs that urgently need safe and effective new treatments. Referring to the collaboration agreement with CPDD, Dr Stuart WG Smith, Founder and CEO of Scottish medical charity Developing World Health, commented: "Developing World Health's objective is to facilitate the development of new treatments for NTDs. This collaboration will mean that we can expedite the development of novel treatments and help save the lives of many more children and adults afflicted by the scourge of NTD's."

Dr Rick Tidwell, Director of the Consortium for Parasitic Drug Development (CPDD) based at the University of North Carolina at Chapel Hill, commented: "This is a very welcome and exciting strategic partnership and brings together additional expertise to increase funding and collaboration opportunities for the Consortium and enhance the rapid development of novel treatments for NTDs such as African sleeping sickness and leishmaniasis."

The partnership means DWH and CPDD can effectively source funding from commercial, government and not-for-profit organisations to develop and / or improve effective treatments for preventable, treatable diseases like leishmaniasis, African trypanosomiasis (sleeping sickness), Chagas disease (American trypanosomiasis) and Dengue.

The partnership enables the charity to bridge the 'missing link' between academics requiring research funding and the pharmaceutical industry interested in tackling these devastating tropical diseases.

The CPDD currently has in its portfolio, a novel compound shown to be 100% curative in models of late-stage stage African Trypanosomiasis ("sleeping sickness"). This disease is caused by microscopic parasites of the species Trypanosoma brucei and is transmitted by the tsetse fly found only in rural Africa. Currently, about 10,000 new cases each year are reported to the World Health Organization. However, it is believed that many cases go undiagnosed and unreported. Sleeping sickness is fatal if left untreated.

The CPDD brings together some of the world's top experts in drug development and delivery from UNC-Chapel Hill, Georgia State University, the University of Glasgow, Ohio State University, the Swiss Tropical Institute, and the Kenya Trypanosomiasis Research Institute among others.


'/>"/>

Contact: Colin Hutchison
chutchison@3x1.com
44-131-225-7700
University of North Carolina School of Medicine
Source:Eurekalert

Related medicine news :

1. Wild Scottish sheep could help explain differences in immunity
2. Heart disease study highlights Scottish ethnic groups most at risk
3. TheReliefPlace.com Launches Online Store “The Relief Shop” - What Does this Medical Supply Store Carry and How Can They Help You?
4. Medical Transcription Services and EHR Provider MxSecure Launches New Enhanced Website with Goal of Improved Physician Productivity
5. Medical Training School, Pima Medical Institute Offering First Bachelor's Degree Program
6. FDA Seeks Reduction in Radiation From Medical Scans
7. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
8. University of Virginia Health System Medical Laboratories Selects Sunquest's Specimen Collection Solution
9. Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements
10. Centene Corporation Hosts Medical Management Systems Update in New York City
11. CelebrityDiagnosis.com Nominated as Best New Medical Blog of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... MALVERN, PA (PRWEB) , ... ... ... Management ("CSM"), a Great Point Partners ("GPP") portfolio company, today announced it ... Clinical Supplies ("TCS"). TCS was previously a subsidiary of Chiltern International ...
(Date:12/5/2016)... ... December 05, 2016 , ... The new knee compression ... looking to buy neoprene knee sleeves for lifting and any sport that ... heavily on two main aspects to provide a higher quality knee sleeve performance. Firstly ...
(Date:12/5/2016)... ... December 05, 2016 , ... A newly released ... improves the reproducibility and accuracy of placing precordial electrodes with little cognitive effort ... the last 60 years, studies have shown that single electrode misplacement is one ...
(Date:12/4/2016)... ... December 03, 2016 , ... Houston ... the 2016 Anti-Aging & Beauty Awards at The Aesthetic & Anti-aging Medicine ... Medicine European Congress (AMEC) brings together the industry’s leading scientific experts, speakers, ...
(Date:12/4/2016)... ... ... Responsible dental care hinges on regular brushing of the teeth. However, just brushing ... inspired an inventor from Las Vegas, Nev., to design the BRUSH PROPER. , ... bad techniques of brushing the teeth in order to prevent cavities," he said. "Children ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... M ichael ... Chairman   Mission Therapeutics, a drug discovery ... to treat cancer, neurodegenerative and other diseases, announces that Dr ... effective January 1 st 2017. Dr Colin Goddard ... Director in July 2015. Michael Moore , Mission,s Founder ...
(Date:12/4/2016)... DIEGO , Dec. 3, 2016 Johnson & ... on behalf of purchasers of Zimmer Biomet Holdings, Inc. (NYSE: ... 7, 2016 through October 31, 2016 (the "Class Period"). ... designs, manufactures, and markets orthopaedic reconstructive products, such as knee ... ...
(Date:12/4/2016)... 2016  Results from the Phase II SUSTAIN study ... reduced the median annual rate of sickle cell-related pain ... 2.98, p=0.010) in patients with or without hydroxyurea therapy ... being featured in the official press briefing at the ... Meeting and presented during the Plenary Scientific Session tomorrow ...
Breaking Medicine Technology: